source
- Tyra Biosciences shares tumble as bladder cancer pill shows lower-than-expected complete responseTyra Biosciences presented Phase 2 SURF302 data for its investigational oral drug dabogratinib in patients with low‑grade intermediate‑risk non‑muscle invasive bladder cancer. The trial reported th…
- August 2026 biopharma layoffs affect just over 500 workers, a 90% drop from a year earlierIn August 2026, twelve biotech and pharmaceutical firms announced workforce reductions, impacting a total of about 526 employees. This represents a sharp 90% decline in the number of people affecte…